80.76
price up icon2.17%   1.87
after-market アフターアワーズ: 80.77 0.010 +0.01%
loading
前日終値:
$78.89
開ける:
$79.17
24時間の取引高:
431.21K
Relative Volume:
0.69
時価総額:
$6.64B
収益:
$51.48M
当期純損益:
$-315.00M
株価収益率:
-22.62
EPS:
-3.5708
ネットキャッシュフロー:
$-244.00M
1週間 パフォーマンス:
+3.15%
1か月 パフォーマンス:
-5.08%
6か月 パフォーマンス:
+18.77%
1年 パフォーマンス:
+173.31%
1日の値動き範囲:
Value
$77.99
$80.78
1週間の範囲:
Value
$77.99
$81.42
52週間の値動き範囲:
Value
$28.06
$103.00

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
名前
Kymera Therapeutics Inc
Name
セクター
Healthcare (1113)
Name
電話
857-285-5314
Name
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
職員
253
Name
Twitter
Name
次回の収益日
2026-04-30
Name
最新のSEC提出書
Name
KYMR's Discussions on Twitter

Compare KYMR vs VRTX, REGN, ARGX, ALNY, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
KYMR icon
KYMR
Kymera Therapeutics Inc
80.76 6.49B 51.48M -315.00M -244.00M -3.5708
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
435.92 110.28B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
634.42 66.98B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
808.61 50.15B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
295.50 39.71B 4.29B 577.22M 641.34M 4.2086
RVMD icon
RVMD
Revolution Medicines Inc
154.89 32.22B 742.00K -1.37B -1.07B -7.0731

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-16 再開されました Jefferies Buy
2026-01-28 再開されました Barclays Overweight
2026-01-06 ダウングレード Wolfe Research Outperform → Peer Perform
2025-11-03 再開されました Guggenheim Buy
2025-10-24 繰り返されました B. Riley Securities Buy
2025-10-21 開始されました Mizuho Outperform
2025-09-18 繰り返されました H.C. Wainwright Buy
2025-09-17 開始されました Barclays Overweight
2025-09-16 開始されました RBC Capital Mkts Outperform
2025-07-30 再開されました B. Riley Securities Buy
2025-07-03 再開されました Morgan Stanley Overweight
2025-06-03 アップグレード B. Riley Securities Neutral → Buy
2025-06-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-06-02 アップグレード BofA Securities Neutral → Buy
2025-05-20 再開されました Stifel Buy
2025-03-13 開始されました Citigroup Buy
2024-12-10 開始されました BTIG Research Buy
2024-12-06 開始されました BMO Capital Markets Market Perform
2024-12-02 アップグレード Wells Fargo Equal Weight → Overweight
2024-11-18 開始されました Stephens Overweight
2024-09-09 再開されました Leerink Partners Outperform
2024-08-26 アップグレード Wolfe Research Peer Perform → Outperform
2024-04-22 開始されました Oppenheimer Outperform
2024-02-15 開始されました Wolfe Research Peer Perform
2024-01-04 アップグレード JP Morgan Neutral → Overweight
2024-01-03 ダウングレード BofA Securities Buy → Neutral
2023-12-19 ダウングレード Wells Fargo Overweight → Equal Weight
2023-06-30 開始されました Truist Buy
2023-05-05 アップグレード Raymond James Mkt Perform → Outperform
2022-12-06 ダウングレード Credit Suisse Outperform → Neutral
2022-11-08 開始されました Raymond James Mkt Perform
2022-08-15 開始されました Jefferies Buy
2022-08-03 開始されました Goldman Buy
2022-07-20 開始されました SVB Leerink Mkt Perform
2022-04-28 開始されました Credit Suisse Outperform
2022-03-10 開始されました JP Morgan Neutral
2022-02-10 開始されました Wells Fargo Overweight
2021-09-30 開始されました B. Riley Securities Neutral
2021-09-30 開始されました Stifel Buy
2021-09-10 ダウングレード BofA Securities Buy → Neutral
2021-05-21 開始されました UBS Buy
2021-04-14 開始されました Berenberg Buy
2020-12-04 開始されました H.C. Wainwright Buy
2020-09-15 開始されました BofA Securities Neutral
2020-09-15 開始されました Cowen Outperform
2020-09-15 開始されました Guggenheim Buy
2020-09-15 開始されました Morgan Stanley Equal-Weight
すべてを表示

Kymera Therapeutics Inc (KYMR) 最新ニュース

pulisher
09:12 AM

Kymera Therapeutics Stays on Track With KT-621 Trials, Teases IRF5 Data - MarketBeat

09:12 AM
pulisher
May 25, 2026

Liquidity Mapping Around (KYMR) Price Events - Stock Traders Daily

May 25, 2026
pulisher
May 22, 2026

Kymera Therapeutics Inc. (KYMR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

May 22, 2026
pulisher
May 21, 2026

Eagle Health Investments LP Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat

May 21, 2026
pulisher
May 20, 2026

CCORF Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $106 - Moomoo

May 20, 2026
pulisher
May 19, 2026

Director at Kymera (NASDAQ: KYMR) exercises 1,000 shares, 9,000 options remain - Stock Titan

May 19, 2026
pulisher
May 19, 2026

Kymera expects KT-579 phase I data in 2H 2026 while targeting KT-621 BROADEN2 enrollment completion by year-end - MSN

May 19, 2026
pulisher
May 19, 2026

Kymera CFO exercises options for 15,000 shares | KYMR Insider Trading - Stock Titan

May 19, 2026
pulisher
May 18, 2026

Which Is a Better Investment, Kymera Therapeutics, Inc. or Nurix Therapeutics, Inc. Stock? - AAII

May 18, 2026
pulisher
May 15, 2026

Kymera presents KT-621 atopic dermatitis trial data at conferences - Investing.com UK

May 15, 2026
pulisher
May 15, 2026

Kymera Therapeutics (KYMR) Valuation Check After New KT-621 And KT-579 Clinical And Preclinical Progress - Yahoo Finance

May 15, 2026
pulisher
May 15, 2026

T. Rowe Price reports 5.46M-share stake in Kymera (KYMR) - Stock Titan

May 15, 2026
pulisher
May 15, 2026

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses - Investing News Network

May 15, 2026
pulisher
May 15, 2026

Kymera presents KT-621 atopic dermatitis trial data at conferences By Investing.com - Investing.com Nigeria

May 15, 2026
pulisher
May 15, 2026

Wellington group holds 3.89M shares in Kymera (KYMR) — 4.76% stake - Stock Titan

May 15, 2026
pulisher
May 15, 2026

Kymera Therapeutics announces presentations on KT-621, a first-in-class, oral Stat6 degrader, at the Society for Investigative Dermatology and American Thoracic Society congresses - marketscreener.com

May 15, 2026
pulisher
May 15, 2026

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses - GlobeNewswire Inc.

May 15, 2026
pulisher
May 14, 2026

Kymera Therapeutics stock (US50153V1061): Featured in psoriasis pipeline report - AD HOC NEWS

May 14, 2026
pulisher
May 14, 2026

Why (KYMR) Price Action Is Critical for Tactical Trading - Stock Traders Daily

May 14, 2026
pulisher
May 13, 2026

BTIG Maintains Kymera Therapeutics (KYMR) Buy Recommendation - MSN

May 13, 2026
pulisher
May 13, 2026

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

May 13, 2026
pulisher
May 12, 2026

Kymera Therapeutics stock (US50153V1061): Director sells $261K in shares amid strong Q1 revenue - AD HOC NEWS

May 12, 2026
pulisher
May 12, 2026

Law firm investigates Kymera Therapeutics for possible breach of fiduciary duties by directors - Pluang

May 12, 2026
pulisher
May 12, 2026

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) - PR Newswire

May 12, 2026
pulisher
May 12, 2026

Kymera Therapeutics director Elena Ridloff sells $261,000 in stock By Investing.com - Investing.com Australia

May 12, 2026
pulisher
May 11, 2026

Kymera Therapeutics director Elena Ridloff sells $261,000 in stock - Investing.com

May 11, 2026
pulisher
May 11, 2026

Kymera (KYMR) director Ridloff exercises options, sells 3,000 shares under 10b5-1 plan - Stock Titan

May 11, 2026
pulisher
May 11, 2026

KYMR (KYMR) Form 144: 3,000-share sale; prior 10b5-1 sales disclosed - Stock Titan

May 11, 2026
pulisher
May 08, 2026

Kymera Therapeutics stock (US50153V1061): Up after Q1 beat and new IBD data for KT-579 degrader cand - AD HOC NEWS

May 08, 2026
pulisher
May 07, 2026

How The Kymera Therapeutics (KYMR) Story Is Shifting Around KT-621 And Degrader Potential - Yahoo Finance

May 07, 2026
pulisher
May 07, 2026

State of New Jersey Common Pension Fund D Makes New $2.61 Million Investment in Kymera Therapeutics, Inc. $KYMR - MarketBeat

May 07, 2026
pulisher
May 06, 2026

CCORF Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $106 - Moomoo

May 06, 2026
pulisher
May 06, 2026

FMR LLC holds 14.3% of Kymera Therapeutics (NASDAQ: KYMR) in 13G/A - Stock Titan

May 06, 2026
pulisher
May 06, 2026

Kymera Therapeutics to Participate in Upcoming May Investor Conferences - Investing News Network

May 06, 2026
pulisher
May 06, 2026

Kymera’s IRF5 degrader shows potential in IBD treatment - BioWorld News

May 06, 2026
pulisher
May 06, 2026

Canaccord Genuity Group Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat

May 06, 2026
pulisher
May 06, 2026

Vanguard Group Inc. Buys 845,922 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat

May 06, 2026
pulisher
May 06, 2026

UBS Group AG Buys 88,314 Shares of Kymera Therapeutics, Inc. $KYMR - MarketBeat

May 06, 2026
pulisher
May 06, 2026

Q2 EPS Estimate for Kymera Therapeutics Boosted by Analyst - MarketBeat

May 06, 2026
pulisher
May 06, 2026

Kymera lines up two May investor webcasts from Las Vegas and New York - Stock Titan

May 06, 2026
pulisher
May 05, 2026

Kymera presents preclinical data for IBD drug candidate KT-579 By Investing.com - Investing.com South Africa

May 05, 2026
pulisher
May 05, 2026

Kymera presents preclinical data for IBD drug candidate KT-579 - Investing.com UK

May 05, 2026
pulisher
May 05, 2026

Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week - Investing News Network

May 05, 2026
pulisher
May 05, 2026

Equities Analysts Issue Forecasts for KYMR Q2 Earnings - MarketBeat

May 05, 2026
pulisher
May 05, 2026

Oral bowel disease drug matched approved therapies in preclinical tests - Stock Titan

May 05, 2026
pulisher
May 04, 2026

Kymera Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:KYMR) 2026-05-04 - Seeking Alpha

May 04, 2026
pulisher
May 04, 2026

Kymera Therapeutics Q1 2026 earnings preview - MSN

May 04, 2026
pulisher
May 04, 2026

Kymera Therapeutics, Inc. Rings the Nasdaq Stock Market Opening Bell in Celebration of its 10-Year Anniversary - Nasdaq

May 04, 2026
pulisher
May 04, 2026

Kymera Therapeutics, Inc. Rings the Opening Bell in Celebration of its 10-Year Anniversary - Nasdaq

May 04, 2026
pulisher
May 04, 2026

H.C. Wainwright Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $134 - Moomoo

May 04, 2026

Kymera Therapeutics Inc (KYMR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Kymera Therapeutics Inc (KYMR) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Jacobs Bruce N.
Chief Financial Officer
May 18 '26
Option Exercise
2.08
15,000
31,200
247,588
Ridloff Elena
Director
May 11 '26
Option Exercise
31.20
3,000
93,600
3,000
Ridloff Elena
Director
May 11 '26
Sale
87.00
3,000
261,000
0
$29.66
price down icon 1.49%
$92.29
price up icon 0.12%
$108.87
price up icon 2.60%
$53.85
price down icon 0.94%
ONC ONC
$302.59
price down icon 2.50%
$154.89
price up icon 2.21%
大文字化:     |  ボリューム (24 時間):